CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease
How to prepare an accurate paper press kit? Illustrated guide
Y. Courtney, M. Pandit, L. S. van Dam, S. Younis, S. Rasouli, M. Zhang et al. · DOI: 10.64898/2026.10.24.761515 · Summary page
Why cover this story this week?
An immune reset reaches virus-infected B cells
A clinical preprint offers a possible explanation for durable remission after CD19-CAR T-cell therapy in autoimmune disease. Researchers used EBV-seq to profile Epstein–Barr virus-infected B cells in patients receiving CAR T cells or rituximab, and reconstructed antibodies from those cells to test what they recognized. Before treatment, the infected cells showed features of immune activation and carried antibodies directed against the body’s own targets.
CAR T-cell treatment, unlike rituximab, depleted these infected cells. The returning population was less mutated and largely non-autoreactive, consistent with infection of newly generated B cells rather than persistence of the old repertoire. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated patients versus 0/15 rituximab-treated patients. Laboratory experiments also found that infected B cells resisted the tested antibody treatments but could be killed by CAR T cells or a CD19 T-cell engager. The results connect an immune-repertoire reset with remission, although the comparison does not establish that removal of EBV-infected autoreactive cells caused the clinical benefit.
Editorial context written by AI from abstracts, not independent scientific validation. The kit and its verified quotes rely on the source paper, not on this letter.
Talk about a paper in public without overstating it: yours, one you are asked to comment on, or one you write about as a journalist.
- Your paper: a draft release for your press office, the questions journalists will ask with what the paper lets you answer, the likely misreadings, a lay summary and a short thread.
- Asked to comment: what the paper shows and does not, its strengths and weaknesses with their passages, and what would settle its main claim.
- Writing about it as a journalist: reporting angles, the wording to check before publication, and the questions to ask the authors.
- For everyone: findings with their passages checked word for word, the novelty set against the closest earlier papers, a hype check, figures with their credit, and researchers for an outside view who have not signed with the authors.